Search Results - "Qiang, Huiping"

New advances in antiangiogenic combination therapeutic strategies for advanced non-small cell lung cancer by Qiang, Huiping, Chang, Qing, Xu, Jianlin, Qian, Jialin, Zhang, Yanwei, Lei, Yuqiong, Han, Baohui, Chu, Tianqing

“…Purpose Tumor growth relies on the sufficient blood supply and continuously requires new blood vessels to maintain, which lead to vascular abnormalities…”
Get full text

467 A real-world retrospective study of immunotherapy in NSCLC patients with KRAS mutation by Qiang, Huiping, Zhong, Hua

“…BackgroundKRAS mutations occur in about 15–20% of patients with lung cancer. Due to the small size and smooth surface of KRAS protein, it is difficult to…”
Get full text

Mining GEO and TCGA Database for Immune Microenvironment of Lung Squamous Cell Carcinoma Patients With or Without Chemotherapy by Qiang, Huiping, Li, Jiaqi, Chang, Qing, Shen, Yinchen, Qian, Jialin, Chu, Tianqing

“…Chemotherapy is the main treatment for patients with lung squamous cell carcinoma (LUSC). However, how chemotherapy affects their immune system is rarely…”
Get full text

Effective low-dose Anlotinib induces long-term tumor vascular normalization and improves anti-PD-1 therapy by Fan, Peng, Qiang, Huiping, Liu, Zhenhua, Zhao, Qi, Wang, Ying, Liu, Tingkun, Wang, Xuan, Chu, Tianqing, Huang, Yuhui, Xu, Wei, Qin, Songbing

“…Anlotinib is a new multitarget tyrosine kinase inhibitor for tumor angiogenesis, and its monotherapy exhibits a decent clinical efficacy. However, the process…”
Get full text

Comparison of the efficacy and safety in the treatment strategies between chemotherapy combined with antiangiogenic and with immune checkpoint inhibitors in advanced non-small cell lung cancer patients with negative PD-L1 expression: A network meta-analysis by Li, Jiaqi, Chen, Yingjie, Hu, Fan, Qiang, Huiping, Chang, Qing, Qian, Jialin, Shen, Yinchen, Cai, Yong, Chu, Tianqing

“…In the first-line treatment of advanced non-small cell lung cancer (NSCLC), for those patients with negative PD-L1 expression, which treatment strategy has the…”
Get full text

Anti-angiogenic therapy or immunotherapy? A real-world study of patients with advanced non-small cell lung cancer with EGFR/HER2 exon 20 insertion mutations by Li, Jiaqi, Xie, Mengqing, Zhao, Ruiying, Qiang, Huiping, Chang, Qing, Qian, Jialin, Lu, Haijiao, Shen, Yinchen, Han, Yuchen, Su, Chunxia, Chu, Tianqing

“…For patients with EGFR/HER2 exon20 insertions, platinum-containing double-drug chemotherapy is still the standard treatment method. First-generation TKIs have…”
Get full text

Epidermal Growth Factor Receptor Mutation Status and Response to Tyrosine Kinase Inhibitors in Advanced Chinese Female Lung Squamous Cell Carcinoma: A Retrospective Study by Chang, Qing, Qiang, Huiping, Qian, Jialin, Lei, Yuqiong, Lu, Jiahuan, Feng, Hui, Zhao, Yiming, Han, Baohui, Zhang, Yanwei, Chu, Tianqing

“…The frequency of epidermal growth factor receptor (EGFR) mutations and the efficacy of tyrosine kinase inhibitor (TKI) in Chinese female patients with lung…”
Get full text

Dynamic alterations of ctDNA associate with the therapeutic outcome in the advanced non‐small cell lung cancer patients who received sintilimab plus anlotinib regime as 1st line therapy by Chu, Tianqing, Yuan, Jie, Lu, Jun, Nie, Wei, Zhong, Runbo, Zhang, Bo, Zhang, Wei, Shi, Chunlei, Qian, Jialin, Zhang, Yanwei, Zhang, Xueyan, Teng, Jiajun, Gao, Zhiqiang, Lou, Yuqing, Li, Jiaqi, Qiang, Huiping, Zhang, Chao, Li, Jin, Xia, Xuefeng, Zhong, Hua, Han, Baohui

“…[...]we attempted to analyse the association between bTMB and progression-free survival (PFS)/overall survival (OS). [...]we evaluated the predictive value of…”
Get full text

Phase 1b Study of Sintilimab Plus Anlotinib as First-line Therapy in Patients With Advanced NSCLC by Chu, Tianqing, Zhong, Runbo, Zhong, Hua, Zhang, Bo, Zhang, Wei, Shi, Chunlei, Qian, Jialin, Zhang, Yanwei, Chang, Qing, Zhang, Xueyan, Dong, Yu, Teng, Jiajun, Gao, Zhiqiang, Qiang, Huiping, Nie, Wei, Zhao, Yiming, Han, Yuchen, Chen, Ya, Han, Baohui

“…Although the interaction between tumor immune microenvironment and angiogenesis has been well established, evidence supporting the chemo-free combination of…”
Get more information

Impact of PD-L1 expression on the efficacy of first-line crizotinib in advanced ROS1-rearranged NSCLC by Xu, Yingqi, Zhang, Yidan, Qiang, Huiping, Zhong, Hua, Xu, Jianlin, Zhong, Runbo

“…•The predictive accuracy of PD-L1 expression in NSCLC patients with oncogenic drivers, such as those receiving TKI treatment, remains controversial.•We…”
Get full text

Atorvastatin suppressed proliferation and facilitated apoptosis of A549 cells through mediating recruitment of Fas and CD59 in lipid raft by Lu, Jiahuan, Qiang, Huiping, Chu, Tianqing

“…Purpose: Lipid raft facilitated progression of NSCLC and atorvastatin could break cholesterol. The purpose of this study was to determine the potential…”
Get full text

Special issue “The advance of solid tumor research in China”: Real‐world clinical outcomes of alectinib for advanced nonsmall‐cell lung cancer patients with ALK fusion in China by Su, Chunxia, Zhou, Juan, Qiang, Huiping, Zhao, Jing, Chang, Qing, Ji, Xianxiu, Li, Jiaqi, Xie, Mengqing, Chu, Tianqing

“…Global phase 3 trials have demonstrated the priority of several next‐generation anaplastic lymphoma kinase‐tyrosine kinase inhibitors (ALK‐TKIs). However,…”
Get full text

Clinical characteristics and prognostic factors of surgically resected combined small cell lung cancer: a retrospective study by Lei, Yuqiong, Feng, Hui, Qiang, Huiping, Shang, Zhanxian, Chang, Qing, Qian, Jialin, Zhang, Yanwei, Zhong, Runbo, Fan, Xiaohong, Chu, Tianqing

“…•SCLC/LCNEC was the most common type of C-SCLC.•SCLC/LCNEC patients' DFS and OS were also longer than other combined types.•Adjuvant chemotherapy of EP/EC…”
Get full text

Treatment efficacy of HER2-mutant lung adenocarcinoma by immune checkpoint inhibitors: a multicenter retrospective study by Chu, Xiangling, Qiang, Huiping, Xie, Mengqing, Li, Xing, Zhao, Jing, Wu, Yan, Zhou, Juan, Ye, Jinyan, Zhao, Chao, Han, Chaonan, Chu, Tianqing, Su, Chunxia

“…Background Despite the remarkable clinical advance of immune checkpoint inhibitors (ICIs) in the treatment of lung cancer, there are limited studies focused on…”
Get full text

Neoadjuvant immunology therapy in patients with non-small cell lung cancer and chronic obstructive pulmonary disease by Chang, Qing, Li, Jiaqi, Zhu, Yan, Qiang, Huiping, Lu, Haijiao, Shen, Yinchen, Wang, Shuyuan, Qian, Jialin, Chu, Tianqing

Get full text

EGFR Tyrosine Kinase Inhibitor (TKI) Combined With Concurrent or Sequential Chemotherapy for Patients With Advanced Lung Cancer and Gradual Progression After First-Line EGFR-TKI Therapy: A Randomized Controlled Study by Chang, Qing, Xu, Jianlin, Qiang, Huiping, Teng, Jiajun, Qian, Jialin, Lv, Minfang, Zhang, Yanwei, Lou, Yuqing, Zhao, Yizhuo, Zhong, Runbo, Han, Baohui, Chu, Tianqing

“…Continuing tyrosine kinase inhibitor (TKI) therapy may be beneficial when patients with non–small-cell lung cancer and EGFR mutations experience gradual…”
Get full text

Anlotinib Combined with Anti‐PD1 Potentiates Anti‐Tumor Immunity via Immunogenic Cell Death and Macrophage Reprogramming by Zou, Benkun, Jiang, Haohua, Liu, Hongyu, Lu, Jun, Qiang, Huiping, Lu, Mingfang, Yu, Lian, Zhong, Hua, Chu, Tianqing, Han, Baohui

“…The combination therapy of targeted drugs and immune checkpoint inhibitors has shown prominent success. In addition to blocking mutated oncogene downstream…”
Get full text

A retrospective study for prognostic significance of type II diabetes mellitus and hemoglobin A1c levels in non-small cell lung cancer patients treated with pembrolizumab by Shen, Yinchen, Li, Jiaqi, Qiang, Huiping, Lei, Yuqiong, Chang, Qing, Zhong, Runbo, Stella, Giulia Maria, Gelsomino, Francesco, Kim, Yeon Wook, Abed, Afaf, Qian, Jialin, Chu, Tianqing

Get full text

Pembrolizumab monotherapy or combination therapy for bone metastases in advanced non-small cell lung cancer: a real-world retrospective study by Qiang, Huiping, Lei, Yuqiong, Shen, Yinchen, Li, Jiaqi, Zhong, Hua, Zhong, Runbo, Zhang, Xueyan, Chang, Qing, Lu, Jiahuan, Feng, Hui, Zhu, Yan, Addeo, Alfredo, Banna, Giuseppe L., Oh, In-Jae, Qian, Jialin, Chu, Tianqing

Get full text

Special issue "The advance of solid tumor research in China": Real-world clinical outcomes of alectinib for advanced non-small-cell lung cancer patients with ALK fusion in China by Su, Chunxia, Zhou, Juan, Qiang, Huiping, Zhao, Jing, Chang, Qing, Ji, Xianxiu, Li, Jiaqi, Xie, Mengqing, Chu, Tianqing

“…Global phase 3 trials have demonstrated the priority of several next-generation anaplastic lymphoma kinase-tyrosine kinase inhibitors (ALK-TKIs). However,…”
Get full text